PT  - JOURNAL ARTICLE
AU  - Baunez, Christelle
AU  - Degoulet, Mickael
AU  - Luchini, Stéphane
AU  - Pintus, Patrick A.
AU  - Teschl, Miriam
TI  - An Early Assessment of Curfew and Second COVID-19 Lock-down on Virus Propagation in France
AID  - 10.1101/2020.11.11.20230243
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.11.20230243
4099  - http://medrxiv.org/content/early/2020/11/13/2020.11.11.20230243.short
4100  - http://medrxiv.org/content/early/2020/11/13/2020.11.11.20230243.full
AB  - This note provides an early assessment of the reinforced measures to curb the COVID-19 pandemic in France, which include a curfew of selected areas and culminate in a second COVID-19-related lock-down that started on October 30, 2020 and is still ongoing. We analyse the change in virus propagation across age groups and across départements using an acceleration index introduced in Baunez et al. (2020). We find that while the pandemic is still in the acceleration regime, acceleration decreased notably with curfew measures and this more rapidly so for the more vulnerable population group, that is, for people older than 60. Acceleration continued to decline under lock-down, but more so for the active population under 60 than for those above 60. For the youngest population aged 0 to 19, curfew measures did not reduce acceleration but lock-down does. This suggests that if health policies aim at protecting the elderly population generally more at risk to suffer severe consequences from COVID-19, curfew measures may be effective enough. However, looking at the departmental map of France, we find that curfews have not necessarily been imposed in départements where acceleration was the largest.JEL Classification Numbers I18; H12Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData publicly available at Agence Santé Publique France